成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Anti-infection PI3K/Akt/mTOR Apoptosis
  3. HCV Parasite Akt Ferroptosis
  4. Artemisinin

Artemisinin  (Synonyms: 青蒿素; Qinghaosu; NSC 369397)

目錄號: HY-B0094 純度: ≥98.0%
COA 產(chǎn)品使用指南

Artemisinin (Qinghaosu) 是一種倍半萜烯內(nèi)酯，從黃花蒿 (Artemisia annua L.) 植物的地上部分分離的抗瘧疾活性分子。Artemisinin 以劑量依賴性方式降低 pAKT 來抑制 AKT 信號通路。Artemisinin 可減少癌細胞的增殖，遷移，侵襲，腫瘤發(fā)生和轉(zhuǎn)移，同時 Artemisinin 有神經(jīng)保護作用。

MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務

Artemisinin Chemical Structure

Artemisinin Chemical Structure

CAS No. : 63968-64-9

1.  客戶無需承擔相應的運輸費用。

2.  同一機構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機構(gòu)（單位）一年內(nèi)

     可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥737
In-stock
5 mg ￥100
In-stock
10 mg ￥150
In-stock
50 mg ￥300
In-stock
100 mg ￥480
In-stock
200 mg ￥670
In-stock
500 mg ￥1116
In-stock
1 g   詢價  
5 g   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of Artemisinin:

    Artemisinin purchased from MCE. Usage Cited in: Biomed Pharmacother. 2019 Oct;118:109383.  [Abstract]

    ART (Artemisinin) suppresses the phosphorylation of AKT in UMRC-2 xenograft tumor. Tumors are homogenized in RIPA buffer. The protein levels were measured by western blot analysis.

    查看 Parasite 亞型特異性產(chǎn)品:

    查看 Akt 亞型特異性產(chǎn)品:

    • 生物活性

    • 純度 & 產(chǎn)品資料

    • 參考文獻

    生物活性

    Artemisinin (Qinghaosu), a sesquiterpene lactone, is an anti-malarial agent isolated from the aerial parts of Artemisia annua L. plants[1]. Artemisinin inhibits AKT signaling pathway by decreasing pAKT in a dose-dependent manner. Artemisinin reduces cancer cell proliferation, migration, invasion, tumorigenesis and metastasis and has neuroprotective effects[2].

    IC50 & Target[2]

    Plasmodium

     

    細胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A-375 IC50
    > 50 μM
    Compound: ART
    Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay
    		[PMID: 29597166]
    A-375 IC50
    > 50 μM
    Compound: Artemisinin
    Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29789258]
    A-431 IC50
    39.03 μM
    Compound: Artemisinin
    Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31546197]
    A549 IC50
    > 300 μM
    Compound: Artemisinin
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 31945642]
    A549 IC50
    > 50 μM
    Compound: ART
    Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
    		[PMID: 29597166]
    A549 IC50
    > 50 μM
    Compound: ART
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    		[PMID: 30837097]
    A549 IC50
    > 50 μM
    Compound: Artemisinin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29789258]
    A549 IC50
    39.03 μM
    Compound: Artemisinin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31546197]
    A549 IC50
    9.85 μM
    Compound: Artemisinin
    Anticancer activity against human A549 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
    		[PMID: 34303874]
    ADR5000 cell line EC50
    26.9 μM
    Compound: 1
    Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    		[PMID: 29887512]
    BEAS-2B IC50
    7.53 μM
    Compound: Artemisinin
    Anticancer activity against human BEAS-2B cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
    Anticancer activity against human BEAS-2B cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
    		[PMID: 34303874]
    BT-549 IC50
    40 μM
    Compound: Artemisinin
    Antiproliferative activity against human BT-549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
    Antiproliferative activity against human BT-549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
    		[PMID: 27010926]
    CCRF-CEM EC50
    36.9 μM
    Compound: 1
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    		[PMID: 29887512]
    COLO 205 IC50
    39.03 μM
    Compound: Artemisinin
    Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31546197]
    HCT-116 IC50
    > 50 μM
    Compound: ART
    Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
    		[PMID: 29597166]
    HCT-15 IC50
    > 300 μM
    Compound: Artemisinin
    Antiproliferative activity against human HCT-15 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human HCT-15 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 31945642]
    HEK293 IC50
    > 120 nM
    Compound: Artemisinin
    Cytotoxicity against HEK293 cells by alamar blue assay
    Cytotoxicity against HEK293 cells by alamar blue assay
    		[PMID: 27212070]
    HEK293 CC50
    > 26 μM
    Compound: Artemisinin
    Cytotoxicity against human HEK293 cells assessed as cell viability measured for 24 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as cell viability measured for 24 hrs by MTT assay
    		[PMID: 34303874]
    HepG2 CC50
    > 30 μM
    Compound: ART
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay
    		[PMID: 33620219]
    HepG2 IC50
    > 300 μM
    Compound: Artemisinin
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 31945642]
    HepG2 IC50
    > 50 μM
    Compound: ART
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    		[PMID: 30837097]
    HepG2 IC50
    4.09 μM
    Compound: Artemisinin
    Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
    		[PMID: 34303874]
    HL-60 IC50
    40 μM
    Compound: Artemisinin
    Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 27010926]
    Huh-7 CC50
    > 100 μg/mL
    Compound: Artemisinin
    Cytotoxicity against human HuH7 cells after 72 hrs by MTT assay
    Cytotoxicity against human HuH7 cells after 72 hrs by MTT assay
    		[PMID: 26922227]
    HUVEC IC50
    1.1 μM
    Compound: ART
    Cytotoxicity against HUVEC assessed as reduction in cell number after 48 hrs by MTT assay
    Cytotoxicity against HUVEC assessed as reduction in cell number after 48 hrs by MTT assay
    		[PMID: 28549888]
    K562 IC50
    39.03 μM
    Compound: Artemisinin
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31546197]
    L02 IC50
    > 100 μM
    Compound: ART
    Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay
    		[PMID: 30837097]
    L02 IC50
    > 50 μM
    Compound: ART
    Antiproliferative activity against human L02 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human L02 cells after 72 hrs by CCK-8 assay
    		[PMID: 29597166]
    L02 IC50
    > 50 μM
    Compound: Artemisinin
    Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29789258]
    L02 IC50
    0.43 μM
    Compound: 1b; ARS
    Cytotoxicity against human L02 cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 33636536]
    L02 IC50
    8.25 μM
    Compound: Artemisinin
    Anticancer activity against human L02 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
    Anticancer activity against human L02 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
    		[PMID: 34303874]
    L6 CC50
    > 350 μM
    Compound: ART
    Cytotoxicity against rat L6 cels assessed as reduction in cell viability after 72 hrs by Alamar Blue dye-based fluorometric analysis
    Cytotoxicity against rat L6 cels assessed as reduction in cell viability after 72 hrs by Alamar Blue dye-based fluorometric analysis
    		[PMID: 30615444]
    L6 IC50
    450 μM
    Compound: ART
    Cytotoxicity against rat L6 cells after 70 hrs by alamar blue staining based fluorometric assay
    Cytotoxicity against rat L6 cells after 70 hrs by alamar blue staining based fluorometric assay
    		[PMID: 28279559]
    L6 IC50
    450.5 μM
    Compound: art
    Cytotoxicity against rat L6 cells after 70 hrs by Alamar blue assay
    Cytotoxicity against rat L6 cells after 70 hrs by Alamar blue assay
    		[PMID: 33148495]
    L6 IC50
    450.5 μM
    Compound: ART
    Cytotoxicity in rat L6 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay
    Cytotoxicity in rat L6 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay
    		[PMID: 30962114]
    L6 IC50
    450.5 μM
    Compound: ART
    Cytotoxicity against rat L6 cells assessed as reduction in cell viability after 72 hrs by Alamar blue assay
    Cytotoxicity against rat L6 cells assessed as reduction in cell viability after 72 hrs by Alamar blue assay
    		[PMID: 27344215]
    MCF7 IC50
    > 50 μM
    Compound: ART
    Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
    		[PMID: 30837097]
    MCF7 IC50
    > 50 μM
    Compound: Artemisinin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29789258]
    MCF7 IC50
    1.4 x 10-4 μM
    Compound: ART
    Cytotoxicity against human MCF7 cells assessed as reduction in cell number after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell number after 48 hrs by MTT assay
    		[PMID: 28549888]
    MDA-MB-231 IC50
    > 100 μM
    Compound: ART
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
    		[PMID: 30837097]
    MDA-MB-231 IC50
    > 50 μM
    Compound: Artemisinin
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29789258]
    MDA-MB-231 IC50
    39.03 μM
    Compound: Artemisinin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31546197]
    MRC5 CC50
    > 25 μM
    Compound: Artemisinin
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 36282784]
    MRC5 IC50
    50.3 μM
    Compound: Artemisinin
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition and measured after 2 days by WST-8 assay
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition and measured after 2 days by WST-8 assay
    		[PMID: 35512262]
    PC-12 IC50
    > 50 μM
    Compound: ART
    Antiproliferative activity against rat PC12 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against rat PC12 cells after 72 hrs by CCK-8 assay
    		[PMID: 29597166]
    PC-3 IC50
    39.03 μM
    Compound: Artemisinin
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31546197]
    SH-SY5Y IC50
    > 50 μM
    Compound: ART
    Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CCK-8 assay
    		[PMID: 29597166]
    SH-SY5Y IC50
    > 50 μM
    Compound: Artemisinin
    Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29789258]
    SMMC-7721 IC50
    0.63 μM
    Compound: 1b; ARS
    Cytotoxicity against human SMMC-7721 cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human SMMC-7721 cells assessed as cell viability after 24 hrs by MTT assay
    		[PMID: 33636536]
    U-87MG ATCC IC50
    > 50 μM
    Compound: Artemisinin
    Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 29789258]
    Vero IC50
    > 16.86 μM
    Compound: Artemisinin
    Cytotoxicity against African green monkey Vero cells after 48 hrs by neutral red uptake assay
    Cytotoxicity against African green monkey Vero cells after 48 hrs by neutral red uptake assay
    		[PMID: 27936446]
    體外研究
    (In Vitro)

    Artemisinin (Qinghaosu) (25 or 50 μM; 24 hours) 濃度依賴性地抑制 Aβ25-35 誘導的 PC12 細胞毒性[1]。
    Artemisinin (1-100 μM; 24 hours) 以劑量依賴性方式選擇性地抑制癌細胞生長，其對 UMRC-2 細胞和 CAKI-2 細胞的 IC50 值分別為23.97, 31.30 μM[2]。
    Artemisinin (25, 50 μM; 24 hours) 以劑量依賴性方式抑制 UMRC-2 和 CAKI-2 細胞中 AKT 的磷酸化[2]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Cytotoxicity Assay[1]

    Cell Line: PC12 cells
    Concentration: 25 or 50 μM
    Incubation Time: 24 hours
    Result: Protected and rescue PC12 cells against Aβ25-35-induced cell death.

    Cell Viability Assay[2]

    Cell Line: RCC cells, RCC cell lines UMRC-2 and CAKI-2, and normal renal cell HK-2
    Concentration: 1, 5, 10, 50, and 100?μM
    Incubation Time: 24 hours
    Result: Selectively inhibited cancer cell growth in a dose-dependent manner.

    Western Blot Analysis[2]

    Cell Line: UMRC-2 and CAKI-2 cells
    Concentration: 25, 50?μM
    Incubation Time: 24 hours
    Result: Decreased pAKT in a dose-dependent manner.
    體內(nèi)研究
    (In Vivo)

    Artemisinin (gavage; 20 mg/kg/day; for two weeks) 抑制 UMRC-2 異種移植腫瘤的生長[2]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: 4-6 weeks old male nude mice[2]
    Dosage: 20?mg/kg
    Administration: gavage; every day for two weeks
    Result: Suppressed UMRC-2 xenograft tumor growth.
    Clinical Trial
    分子量

    282.33

    Formula

    C15H22O5
    CAS 號
    性狀

    固體

    顏色

    White to off-white

    中文名稱

    青蒿素
    結(jié)構(gòu)分類
    初始來源
    運輸條件

    Room temperature in continental US; may vary elsewhere.
    儲存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    溶解性數(shù)據(jù)
    細胞實驗： 

    DMSO 中的溶解度 : 50 mg/mL (177.10 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

    H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

    配制儲備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 3.5420 mL 17.7098 mL 35.4195 mL
    5 mM 0.7084 mL 3.5420 mL 7.0839 mL
    查看完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C儲存時，請在1年內(nèi)使用， -20°C儲存時，請在6個月內(nèi)使用。

    • 摩爾計算器

    • 稀釋計算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實驗：

    請根據(jù)您的 實驗動物和給藥方式 選擇適當?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
    ——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (7.37 mM); 澄清溶液

      此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (7.37 mM); 澄清溶液

      此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
    動物溶解方案計算器
    請輸入動物實驗的基本信息：

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數(shù)量

    只
    由于實驗過程有損耗，建議您多配一只動物的量
    請輸入您的動物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
    計算結(jié)果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
    動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請謹慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: ≥98.0%

    參考文獻

    完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C儲存時，請在1年內(nèi)使用， -20°C儲存時，請在6個月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.5420 mL 17.7098 mL 35.4195 mL 88.5489 mL
    5 mM 0.7084 mL 3.5420 mL 7.0839 mL 17.7098 mL
    10 mM 0.3542 mL 1.7710 mL 3.5420 mL 8.8549 mL
    15 mM 0.2361 mL 1.1807 mL 2.3613 mL 5.9033 mL
    20 mM 0.1771 mL 0.8855 mL 1.7710 mL 4.4274 mL
    25 mM 0.1417 mL 0.7084 mL 1.4168 mL 3.5420 mL
    30 mM 0.1181 mL 0.5903 mL 1.1807 mL 2.9516 mL
    40 mM 0.0885 mL 0.4427 mL 0.8855 mL 2.2137 mL
    50 mM 0.0708 mL 0.3542 mL 0.7084 mL 1.7710 mL
    60 mM 0.0590 mL 0.2952 mL 0.5903 mL 1.4758 mL
    80 mM 0.0443 mL 0.2214 mL 0.4427 mL 1.1069 mL
    100 mM 0.0354 mL 0.1771 mL 0.3542 mL 0.8855 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Artemisinin
    目錄號：
    HY-B0094
    需求量：